Sean Park
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Sean Park is a Professor at Mayo Clinic Rochester in the United States. His research areas include radiotherapy techniques, particularly for renal cell carcinoma and prostate cancer, as well as interventions in musculoskeletal oncology. His recent articles focus on innovative methods in MR simulation and the application of antiandrogens in cancer treatment. He is actively involved in advancing clinical practices through rigorous research in radiation therapy.
Recent Grants
Grant: Open
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma
Open Date: 2024-09-01
Close Date: 2029-08-31
Grant: Open
Radiation and dendritic cells to hepatomas to improve immunotherapy response
Open Date: 2022-09-01
Close Date: 2027-08-31
Grant: Close
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma
Open Date: 2021-02-05
Close Date: 2023-01-31
Grant: Close
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR
Open Date: 2016-02-09
Close Date: 2019-01-31
Articles (26)
Year:
2026
Year:
2026
Year:
2026
Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA + ) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA + EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA + EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months ( P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months ( P = 0.003) for PSMA + EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA + EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA + EV was predictive of benefit from SABR ( P = 0.012). Conclusions: PSMA + EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA + EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.
Year:
2025
Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge. Primary endpoints were adverse events and sPD-L1 reduction. Secondary endpoints included overall survival, response, and progression-free survival. Correlative studies included changes in sPD-L1, other immunosuppressive factors, and immune cell phenotypes. Eighteen patients were included. Treatment was well-tolerated, and levels of sPD-L1 were reduced by TPE (mean 78%, p < 0.0001). Soluble PD-L1 suppression predicted overall survival. The overall response rate was 61% (16.7% complete, 44.4% partial, 22.2% stable, and 16.7% progressing). Changes in peripheral immune cell populations and immunosuppressive factors predicted overall survival. sPD-L1 and other circulating immunoregulatory molecules mediate ICI resistance. TPE can reduce these factors and resensitize ICI-refractory melanoma. Patients with persistent elevation or rapid rebound of sPD-L1 experienced inferior outcomes, suggesting that multiple courses of TPE may be necessary. These findings may apply to other ICI-resistant cancers. Trial registration: NCT04581382, ReCIPE-M1 (Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma 1).
Year:
2025
Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.
Year:
2025
Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.
Year:
2025
Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Collaborators (20)
Oliver Sartor
Tulane University School of Medicine
Phuoc T. Tran
University of Maryland
Sundeep Khosla
Mayo Clinic
Liguo Wang
Professor of Biomedical Informatics
Mayo Clinic Minnesota
Daniel D. Billadeau
-
Xianfang Wu
Associate Professor/Staff
Cleveland Clinic
Jace Webster
Full Specialist
University of California, San Francisco
Xu Zhang
Assistant Professor
Mayo Clinic
Aaron Mansfield
Mayo Clinic Minnesota
Robert McWilliams
Mayo Clinic Minnesota
Piet Ost
Ghent University
Peter Harris
Staff Scientist
Washington University in St. Louis
Aadel A. Chaudhuri
Washington University School of Medicine
Haidong Dong
Professor/Consultant
Mayo Clinic Rochester
Jacob Orme
Assistant Professor
Mayo Clinic
Pradeep Chauhan
Assistant Professor
Mayo Clinic
Fabrice Lucien
Assistant Professor
Mayo Clinic Minnesota
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Russell K. Pachynski
Washington University School of Medicine
Christopher A Maher
Washington University in St. Louis
Make your next move.
Prepare your application
Review drafts before you send them.